Table 2.

Correlation between postoperative pathology and clinicopathological features

Parameters	Postoperative pathology		p value
	DCIS only (n = 70)	Invasive ductal carcinoma (n = 48)
Age at operation (years old)
≤ 60	50 (71.4%)	33 (68.8%)
> 60	20 (28.6%)	15 (31.3%)	0.754
Symptoms
Asymptomatic	30 (42.9%)	12 (25.0%)
Symptomatic	40 (57.1%)	36 (75.0%)	0.044
Palpability
Impalpabe	24 (34.3%)	9 (18.8%)
Palpable	46 (65.7%)	39 (81.3%)	0.065
Tumor size (mm)
≤ 20.0	48 (68.6%)	23 (47.9%)
> 20.0	22 (31.4%)	25 (52.1%)	0.024
Biopsy device
Core needle biopsy	32 (45.7%)	35 (72.9%)
Vacuum-assisted biopsy	38 (54.3%)	13 (27.1%)	0.003
Estrogen receptor
Negative	9 (12.9%)	13 (27.1%)
Positive	61 (87.1%)	35 (72.9%)	0.051
Progesterone receptor
Negative	18 (25.7%)	19 (39.6%)
Positive	52 (74.3%)	29 (60.4%)	0.111
HER2
≤ 2	63 (90.0%)	38 (79.2%)
3	7 (10.0%)	10 (20.8%)	0.100
Ki67
≤ 14%	60 (85.7%)	38 (79.2%)
> 14%	10 (14.3%)	10 (20.8%)	0.352
Grade of DCIS
Low, intermediate	63 (90.0%)	35 (72.9%)
High	7 (10.0%)	13 (27.1%)	0.015
Comedonecrosis
Absence	37 (52.9%)	17 (35.4%)
Presence	33 (47.1%)	31 (64.6%)	0.061
Intraductal calcification
Absence	62 (88.6%)	37 (77.1%)
Presence	8 (11.4%)	11 (22.9%)	0.098
Lymphoid infiltrate
Negative, mild	56 (80.0%)	27 (56.3%)
Moderate, severe	14 (20.0%)	21 (43.8%)	0.006
Platelets–lymphocyte ratio
Low	50 (71.4%)	24 (50.0%)
High	20 (28.6%)	24 (50.0%)	0.018
LDH
≤ ULN	63 (90.0%)	42 (87.5%)
> ULN	7 (10.0%)	6 (12.5%)	0.670
CEA
≤ ULN	66 (94.3%)	45 (93.8%)
> ULN	4 (5.7%)	4 (5.7%)	0.904
CA15–3
≤ ULN	69 (98.6%)	46 (95.8%)
> ULN	1 (1.4%)	2 (4.2%)	0.353

DCIS Ductal carcinoma in situ, HER2 Human epidermal growth factor receptor 2, LDH Lactate dehydrogenease, ULN Upper limit of normal, CEA Carcinoembryonic antigen